Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2017

08.03.2016 | Original Article

Initial Lymphocyte Count as Prognostic Indicator for Childhood Immune Thrombocytopenia

verfasst von: Sinan Akbayram, Kamuran Karaman, Murat Dogan, Lokman Ustyol, Mesut Garipardic, Ahmet Faik Oner

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 1/2017

Einloggen, um Zugang zu erhalten

Abstract

Acute ITP is a benign, self-limiting disease. Chronic ITP is diagnosed when thrombocytopenia persists beyond 12 months. The main objective of the present study was to examine whether absolute lymphocyte counts at diagnosis has predictive value with chronic ITP. A total of 601 patients diagnosed as ITP between 1995 and 2014 were retrospectively evaluated. CBCs with differential counts were performed at presentation for 601 patients. Absolute lymphocyte counts at presentation were independently predictive of disease duration. The male to female ratio was almost 1:1 and 25.9 % (156/601) of the patients had chronic ITP. We determined that age >6.75 year, platelet counts >6.950/mm3 and absolute lymphocyte counts ≤2.050/mm3 was associated with a significant risk for developing chronic ITP. Absolute lymphocyte counts at the time of diagnosis were predictive variables for the development of chronic ITP. Further researches are needed to confirm the current finding and to assess the underlying pathophysiology with the course of the ITP in observational studies.
Literatur
1.
Zurück zum Zitat Glanz J, France E, Xu S, Hayes T, Hambidge S (2008) A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Pediatrics 121:e506–e512CrossRefPubMed Glanz J, France E, Xu S, Hayes T, Hambidge S (2008) A population-based, multisite cohort study of the predictors of chronic idiopathic thrombocytopenic purpura in children. Pediatrics 121:e506–e512CrossRefPubMed
2.
Zurück zum Zitat Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393CrossRefPubMed Rodeghiero F, Stasi R, Gernsheimer T et al (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113:2386–2393CrossRefPubMed
3.
Zurück zum Zitat Paling A, Stefan DC (2008) Idiopathic thrombocytopenic purpura in childhood: a 10-year audit. Hematology 13(3):175–180CrossRefPubMed Paling A, Stefan DC (2008) Idiopathic thrombocytopenic purpura in childhood: a 10-year audit. Hematology 13(3):175–180CrossRefPubMed
4.
Zurück zum Zitat Cooper N, Bussel J (2006) The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 133:364–374CrossRefPubMed Cooper N, Bussel J (2006) The pathogenesis of immune thrombocytopaenic purpura. Br J Haematol 133:364–374CrossRefPubMed
5.
Zurück zum Zitat Gernsheimer T (2009) Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist 14:12–21CrossRefPubMed Gernsheimer T (2009) Chronic idiopathic thrombocytopenic purpura: mechanisms of pathogenesis. Oncologist 14:12–21CrossRefPubMed
6.
Zurück zum Zitat Deel MD, Kong M, Cross KP, Bertolone SJ (2013) Absolute lymphocyte counts as prognostic indicators for immune thrombocytopenia outcomes in children. Pediatr Blood Cancer 60(12):1967–1974PubMed Deel MD, Kong M, Cross KP, Bertolone SJ (2013) Absolute lymphocyte counts as prognostic indicators for immune thrombocytopenia outcomes in children. Pediatr Blood Cancer 60(12):1967–1974PubMed
7.
Zurück zum Zitat Ahmed I, Rajpurkar M, Thomas R, Chitlur M (2010) Initial lymphocyte count and the development of persistent/chronic immune thrombocytopenic purpura. Pediatr Blood Cancer 55(3):508–511CrossRefPubMed Ahmed I, Rajpurkar M, Thomas R, Chitlur M (2010) Initial lymphocyte count and the development of persistent/chronic immune thrombocytopenic purpura. Pediatr Blood Cancer 55(3):508–511CrossRefPubMed
8.
Zurück zum Zitat Kuhne T, Buchanan GR, Zimmerman S et al (2003) A prospective comparative study of 2540 infants and children with newly diagnosed ITP from the ICIS Group. J Pediatr 143:605–608CrossRefPubMed Kuhne T, Buchanan GR, Zimmerman S et al (2003) A prospective comparative study of 2540 infants and children with newly diagnosed ITP from the ICIS Group. J Pediatr 143:605–608CrossRefPubMed
9.
Zurück zum Zitat Fogarty PF, Segal JB (2007) The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol 14:515–519CrossRefPubMed Fogarty PF, Segal JB (2007) The epidemiology of immune thrombocytopenic purpura. Curr Opin Hematol 14:515–519CrossRefPubMed
10.
Zurück zum Zitat Hedman A, Henter JI, Hedlund I, Elinder G (1997) Prevalence and treatment of chronic idiopathic thrombocytopenic purpura of childhood in Sweden. Acta Paediatr 86:226–227CrossRefPubMed Hedman A, Henter JI, Hedlund I, Elinder G (1997) Prevalence and treatment of chronic idiopathic thrombocytopenic purpura of childhood in Sweden. Acta Paediatr 86:226–227CrossRefPubMed
11.
Zurück zum Zitat Watts RG (2004) Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama. Clin Pediatr (Phila) 43(8):691–702CrossRef Watts RG (2004) Idiopathic thrombocytopenic purpura: a 10-year natural history study at the childrens hospital of alabama. Clin Pediatr (Phila) 43(8):691–702CrossRef
12.
Zurück zum Zitat Culic S, Labar B, Marusic A, Salamunic I (2006) Correlations among age, cytokines, lymphocyte subtypes, and platelet counts in autoimmune thrombocytopenic purpura. Pediatr Blood Cancer 47:671–674CrossRefPubMed Culic S, Labar B, Marusic A, Salamunic I (2006) Correlations among age, cytokines, lymphocyte subtypes, and platelet counts in autoimmune thrombocytopenic purpura. Pediatr Blood Cancer 47:671–674CrossRefPubMed
Metadaten
Titel
Initial Lymphocyte Count as Prognostic Indicator for Childhood Immune Thrombocytopenia
verfasst von
Sinan Akbayram
Kamuran Karaman
Murat Dogan
Lokman Ustyol
Mesut Garipardic
Ahmet Faik Oner
Publikationsdatum
08.03.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 1/2017
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0664-0

Weitere Artikel der Ausgabe 1/2017

Indian Journal of Hematology and Blood Transfusion 1/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.